Beta Bionics Announces FDA Clearance of Mint Patch Pump; 3D 510(k) Filed

What Happened

• On September 14, 2026, Beta Bionics announced FDA clearance of Mint, its new patch pump for treatment of type 1 diabetes, and disclosed submission of a 510(k) to the FDA for 3D Intelligence, its next‑generation insulin‑dosing algorithm. The company expects a full U.S. commercial launch of Mint in Q1 2027 and anticipates manufacturing capacity of at least 1.5 million disposable units for 2027. Beta Bionics also made an updated corporate presentation available and attached the press release and presentation to the 8‑K.

Key Details

• FDA clearance date announced: September 14, 2026; full U.S. commercial launch expected Q1 2027.
• Manufacturing capacity target: at least 1.5 million disposable units in 2027.
• Expected payer access at launch: ~40% of insured U.S. lives via pharmacy benefit, targeting ≥50% within first year.
• 3D Intelligence 510(k) filed Sept. 14, 2026; intended to power iLet 3D (U.S. commercialization expected by end of 2026, subject to clearance) and Mint 3D (launch with Mint in Q1 2027, subject to clearance).

Why It Matters

• FDA clearance of Mint is a material commercial milestone: it expands Beta Bionics’ product lineup beyond the existing iLet and sets a concrete launch timeline and initial production capacity that could affect near‑term revenue potential.
• The 3D Intelligence submission is important because, if cleared, it would power next‑generation versions of Beta Bionics’ platforms (iLet 3D and Mint 3D), potentially improving product differentiation.
• The filing also highlights risks investors should note: a securities class action was filed on Sept. 4, 2026 alleging misstatements about iLet (company will defend); the company updated risk factors emphasizing dependence on iLet and Mint, regulatory and manufacturing uncertainties, open recalls, and the need for further clearances for new indications or a bihormonal system.
• Real‑world iLet data cited in the filing shows meaningful clinical outcomes (e.g., >84% of analyzed users met ADA hypoglycemia goals and average HbA1c/GMI improvements), which the company uses to support product value but remain subject to regulatory and commercial risks described in the filing.